Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1865-1870

  Morriello, Gregori J ^a   Wendt, Harvey R ^a   Bansal, Alka ^a   Salvo, Jerry Di ^a   Feighner, Scott ^a   He, Jiafang ^a   Hurley, Amanda L ^a   Hreniuk, Donna L ^a   Salituro, Gino M ^a   Reddy, Marat Vijay ^a   Galloway, Sheila M ^a   McGettigan, Katherine K ^a   Laws, George ^a   McKnight, Crystal ^a   Doss, George A ^a   Tsou, Nancy N ^a   Black, Regina M ^a   Morris, Judy ^a   Ball, Richard G ^a   Sanfiz, Anthony T ^a   Streckfuss, Eric ^a   Struthers, Mary ^a   Edmondson, Scott D ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

3 Adrenergic receptor agonist; Pyrrolidine scaffold

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON; CL 316423; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ETHANOLAMINE; L 796568; MIRABEGRON; NITROGEN; PYRROLIDINE DERIVATIVE; RITOBEGRON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC STIMULATION; CHEMICAL BOND; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RHESUS MONKEY; X RAY CRYSTALLOGRAPHY;

ADRENERGIC BETA-AGONISTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; PYRROLIDINES; RECEPTORS, ADRENERGIC, BETA-3;

CANIS FAMILIARIS; MACACA MULATTA; RATTUS;

EID: 79952362760     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.087     Document Type: Article

References (39)

1. J.R.S. Arch, A.T. Ainsworth, M.A. Cawthorne, C. Wilson, and S. Wilson Nature 309 1984 163
2. J.R.S. Arch Proc. Nutr. Soc. 48 1989 215
3. A.D. Strosberg Annu. Rev. Pharmacol. Toxicol. 37 1997 421
4. L.J. Emorine, S. Marullo, M.-M. Briend-Sutren, G. Patey, K. Tate, C. Delavier-Klutchko, and A.D. Strosberg Science 245 1989 1118
5. A.E. Weber Annu. Rep. Med. Chem. 33 1998 193
6. C. Weyer, J.F. Gautier, and E. Danforth Diabetes Metab. 25 1999 11
7. O. Yamaguchi Urology 59 2002 25
8. S. Rathi, S. Kazerounian, K. Banwait, S. Schulz, S.A. Waldman, and S.J. Ratten J. Pharmacol. Exp. Ther. 305 2003 615
9. M. Takeda, K. Obara, T. Mizusawa, Y. Tomita, K. Aria, T. Tsutsui, A. Hatano, K. Takahashi, and S. Nomura J. Pharmacol. Exp. Ther. 288 1999 1367
10. O. Yamaguchi, and C.R. Chapple Neurourol. Urodyn. 26 2007 752
11. P.J. Hieble Curr. Top. Med. Chem. 7 2007 207
12. P. Tyagi, V. Tyagi, N. Yoshimura, M. Chancellor, and O. Yamaguchi Drugs Future 34 2009 635
13. J.A. Lafontaine, R.F. Day, J. Dibrino, J.R. Hadcock, D.M. Hargrove, M. Linhares, K.A. Martin, T.S. Maurer, N.A. Nardone, D.A. Tess, and P. DaSilva-Jardin Bioorg. Med. Chem. Lett. 17 2007 5245
14. A. Hicks, G.P. McCafferty, E. Riedel, N. Aiyar, M. Pullen, C. Evans, T.D. Luce, R.W. Coatney, G.C. Rivera, T.D. Westfall, and J.P. Hieble J. Pharmacol. Exp. Ther. 323 2007 202
15. Maruyama, T.; Suzuki, T.; Onda, K.; Hayakawa, M.; Moritomo, H.; Kimizuka, T.; Matsui, T. U.S. Patent 6,346,532, 2002; Chem. Abstr. 1998, 129, 19801.
16. T.M. Larsen, S. Toubro, M.A. van Baak, K.M. Gottesdiener, P. Larson, and W.H.M. Saris Am. J. Clin. Nutr. 76 2002 780
17. R.J. Mathvink, S.J. Tolman, D. Chitty, M.R. Candelore, M.A. Cascieri, L.F. Colwell, L. Deng, W.P. Feeney, M.J. Forrest, G.J. Hom, E.D. MacIntyre, R.R. Miller, R.A. Stearns, L. Tota, M.J. Wyvratt, M.H. Fisher, and A.E. Weber J. Med. Chem. 43 2000 3832
18. J.D. Bloom, M.D. Dutia, B.D. Johnson, A. Wissner, M.G. Burns, E.E. Largis, J.A. Dolan, and T.H. Claus J. Med. Chem. 35 1992 3081
19. N. Tanaka, T. Tamai, H. Mukaiyama, A. Hirabayashi, H. Muranaka, T. Ishikawa, S. Akahane, and M. Akahane Bioorg. Med. Chem. 9 2001 3265
20. R.J. Mathvink, S.J. Tolman, D. Chitty, M.R. Candelore, M.A. Cascieri, L.F. Colwell, L. Deng, W.P. Feeney, M.J. Forrest, G.J. Hom, E.D. MacIntyre, L. Tota, M.J. Wyvratt, M.H. Fisher, and A.E. Weber Bioorg. Med. Chem. Lett. 10 2000 1971
21. R.A. Stearns, R.R. Miller, W. Tang, G.Y. Kwei, F.S. Tang, R.J. Mathvink, E.M. Naylor, D. Chitty, V.J. Colandrea, A.E. Weber, A.E. Colletti, J.R. Struss, C.A. Keohane, W.P. Feeney, S.A. Iliff, and S.-H.L. Chiu Drug Metab. Dispos. 30 2002 771
22. W. Tang, R.A. Stearns, R.R. Miller, J.S. Ngui, R.J. Mathvink, A.E. Weber, G.Y. Kwei, J.R. Strauss, C.A. Keohane, G.A. Doss, S.-H.L. Chiu, and T. Baillie Drug Metab. Depos. 30 2002 778
23. For the purpose of easier synthetic manipulation, the phenyl analog of L-796,568 was chosen for comparison since it has similar in vitro potency and metabolic properties as L-796,568.
24. G. Liu, D.A. Cogan, and J.A. Ellman J. Am. Chem. Soc. 119 1997 9913
25. K.M. Brinner, and J.A. Ellman Org. Biomol. Chem. 3 2005 2109
26. S. Nahm, and S.M. Weinreb Tetrahedron Lett. 22 1981 3815
27. D. Astruc New J. Chem. 29 2005 42
28. Zhan Catalyst I is available from Zannan Pharma LTD, catalog number RC-301. Patents CN1907992A, US 2007/0043180 A1, PCT WO 2007/003135 A1.
29. 10
30. The major isomer eluted first at retention time of 4.11 min, while the second isomer eluted at 4.56 min.
31. The stereochemistry of the two pyrrolidine chiral centers was determined to be cis based on 2D NOE NMR data (see Supplementary data).
32. Selectivity was assessed by SFC analytical analysis and the effort to improve selectivity was studied via trial and error of changes in the reaction conditions. Original less selective conditions: Dilution 0.02 M and stoichiometric amount (by weight) of the catalyst (resulted in 3:1 mixture of cis/trans).
33. S.D. Goble, L. Wang, K.L. Howell, A. Bansal, R. Berger, L. Brocknier, J. DiSalvo, S. Feighner, B. Harber, J. He, A. Hurley, D. Hreniuk, E. Parmee, M. Robbins, G. Salituro, A. Sanfiz, E. Streckfuss, E. Watkins, A. Weber, M. Struthers, and S.D. Edmondson Bioorg. Med. Chem. Lett. 20 2010 1895
34. J.P. Felix, B.S. Williams, B.T. Priest, R.M. Brochu, I.E. Dick, V.A. Warren, L. Yan, R.S. Slaughter, G.J. Kaczorowski, M.M. Smith, and M. Garcia Assay Drug Dev. Technol. 2 2004 260
35. J.E. Ridings, M.D. Barratt, R. Cary, C.G. Earnshaw, C.E. Eggington, M.K. Ellis, P.N. Judson, J.J. Langowski, C.A. Marchant, M.P. Payne, W.P. Watson, and T.D. Yih Toxicology 106 1996 267
36. N.F. Cariello, J.D. Wilson, B.H. Britt, D.J. Wedd, B. Burlinson, and V. Gombar Mutagenesis 17 2002 321
37. J.E. Miller, K. Vlasakova, W.E. Glaab, and T.R. Skopek Mutat. Res. 578 2005 210
38. B.N. Ames, F.D. Lee, and W.E. Durston PNAS 70 1973 782
39. K. Mortelmans, and E. Zeiger Mutat. Res. 455 2000 29